ClinicalTrials.gg
CompletedNCT02498418Updated Dec 5, 2019Results posted

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

A Phase 3 interventional study of Rifaximin and Xifaxan® in Diarrhea, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
739
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.

Enrollment
2nd of 19
739 · median 210
Started
2016
with 1 other
Phase 3
10 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
1 of 19
Actavis Inc.

Among the 19 studies testing rifaximin in Diarrhea, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 10 in phase 3, and was the 13th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 77 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing rifaximin in Diarrhea, or all of them as a file.
02

Study summary

The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.

Read the detailed description

This is a randomized, placebo-controlled bioequivalent study with a clinical endpoint in the treatment of travelers' diarrhea. After 3 unformed stools are recorded within the 24 hours immediately preceding randomization, participants are to be randomized to receive the generic rifaximin 200 mg oral tablet, Xifaxan (the reference listed drug)200 mg oral tablet, or placebo 3 times daily for 3 days (that is; on Days 1, 2, and 3).

03

Conditions studied

  • Diarrhea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or nonpregnant female aged ≥18 years non-indigenous travelers (for example; visiting students/faculty or international tourists) affected by naturally acquired acute diarrhea. Diarrhea is defined as the passage of at least 3 unformed stools in a 24-hour period. Stools are classified as formed (retains shape), soft (assumes shape of container), or watery (can be poured). When using this classification, both soft and watery stools are unformed and abnormal.
  2. At least 3 unformed stools recorded within the 24 hours immediately preceding randomization.
  3. At least 1 of the following signs and symptoms of enteric infection:

    • abdominal pain or cramps
    • nausea
    • vomiting
    • fecal urgency
    • excessive gas/flatulence
    • tenesmus
  4. Women of have a negative pregnancy test prior to beginning therapy and agree to use effective methods during the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, breast feeding, or planning a pregnancy.
  2. Immediately prior to randomization, acute diarrhea for >72 hours.
  3. Presence of:

    • fever (≥100 degrees fahrenheit [°F] or ≥37.8 degrees celsius [°C]), or
    • hematochezia (blood in stool), or
    • clinical findings suggesting moderate or severe dehydration.
  4. Active, uncontrolled, or diseases or disorders of the heart, lung, kidney, gastrointestinal (GI) tract (other than infectious diarrhea in travelers), or central nervous system.
  5. Administration of any of the following:

    • any antimicrobial agents with an expected activity against enteric bacterial pathogens within 7 days preceding randomization
    • more than 2 doses of a symptomatic antidiarrheal compound such as antimotility agents, absorbent agents, and antisecretory agents within 8 hours preceding randomization
  6. Use of any drug such as aspirin or ibuprofen (Advil), which can cause GI bleeding. Acetaminophen (Tylenol) or paracetamol is acceptable.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
739 participants (actual)

Study arms

  • Experimental
    Generic Rifaximin 200 mg Tablets

    Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.

    Drug: Rifaximin

  • Active comparator
    Xifaxan 200 mg Tablets

    Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.

    Drug: Xifaxan®

  • Placebo comparator
    Placebo

    Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.

    Drug: Placebo Tablet

Interventions

  • Tablets, generic formulation of the brand product.

  • Tablets, brand product.

  • DrugPlacebo Tablet

    Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population

    Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Bioequivalence evaluation between test (generic rifaximin 200 mg tablets) and reference groups (xifaxan 200 mg tablets) was conducted in this endpoint, hence placebo group was not included. Participants who were discontinued early from the study due to lack of treatment effect after completing 9 doses within 72 hours from the time of first dose were included in the PP population using Last Observation Carried Forward (LOCF) method. Additionally, participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea were discontinued and included in the PP population analysis using LOCF.

    Time frame: TOC visit (Day 5, 6 or 7)

  2. Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population

    Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Participants discontinued early for reasons other than "lack of treatment effect after completing 9 doses within 72 hours from the time of first dose" and for "participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea" were included in the mITT population analysis using LOCF.

    Time frame: TOC visit (Day 5, 6 ,or 7)

Secondary outcomes

  1. Time to Last Unformed Stool (TLUS)

    TLUS was defined as the interval beginning with the first dose of study drug and ending with the last unformed stool passed within a period of 120 hours (within 48 hours from the time of last dose \[at 72 hours\]). Mathematically, TLUS was calculated as follows. TLUS (hours) = date/time of last unformed stool within 48 hours from the time of last dose - date/time of first dose.

    Time frame: Day 1 to Day 5

  2. Percentage of Participants Who Achieved Microbiological Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose)

    Participants were considered to have achieved microbiological cure if the pathogen identified at Day 1 is no longer found in the stool at the TOC visit.

    Time frame: TOC visit (Day 5, 6, or 7)

07

Results

Posted Dec 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneGeneric Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo Tablets
Started247248244
Safety population246247244
Modified intent-to-treat population183186180
Per-protocol analysis set182181176
Completed245246238
Not completed226
Withdrew: Lack of efficacy001
Withdrew: Withdrawal by subject203
Withdrew: Lost to follow-up011
Withdrew: Participant taken prohibited medication011

Outcome measures

PrimaryNumber of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population

Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Bioequivalence evaluation between test (generic rifaximin 200 mg tablets) and reference groups (xifaxan 200 mg tablets) was conducted in this endpoint, hence placebo group was not included. Participants who were discontinued early from the study due to lack of treatment effect after completing 9 doses within 72 hours from the time of first dose were included in the PP population using Last Observation Carried Forward (LOCF) method. Additionally, participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea were discontinued and included in the PP population analysis using LOCF.

Time frame:
TOC visit (Day 5, 6 or 7)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population
ParticipantsGeneric Rifaximin 200 mg TabletsXifaxan 200 mg Tablets
Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population9093
Statistical analysis
  • Generic Rifaximin 200 mg Tablets vs Xifaxan 200 mg Tablets · Difference in percentage of participants: -0.0193 · 90% CI -0.11 to 0.07
SecondaryTime to Last Unformed Stool (TLUS)

TLUS was defined as the interval beginning with the first dose of study drug and ending with the last unformed stool passed within a period of 120 hours (within 48 hours from the time of last dose \[at 72 hours\]). Mathematically, TLUS was calculated as follows. TLUS (hours) = date/time of last unformed stool within 48 hours from the time of last dose - date/time of first dose.

Time frame:
Day 1 to Day 5
Reported as:
Median · hours
Time to Last Unformed Stool (TLUS)
hoursGeneric Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo Tablets
Time to Last Unformed Stool (TLUS)65.25 (3.93 to 119.42)65.75 (14.10 to 117.08)67.01 (16.65 to 117.87)
SecondaryPercentage of Participants Who Achieved Microbiological Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose)

Participants were considered to have achieved microbiological cure if the pathogen identified at Day 1 is no longer found in the stool at the TOC visit.

Time frame:
TOC visit (Day 5, 6, or 7)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Microbiological Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose)
percentage of participantsGeneric Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo Tablets
Escherichia coli25.531.917.4
Enterotoxigenic Escherichia coli (ETEC)43.554.568.4
Enteroaggregative Escherichia coli (EAEC)32.027.326.1
Other microorganisms70.681.892.9
Stool microscopy for ova and parasites83.3100.0100.0
PrimaryNumber of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population

Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Participants discontinued early for reasons other than "lack of treatment effect after completing 9 doses within 72 hours from the time of first dose" and for "participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea" were included in the mITT population analysis using LOCF.

Time frame:
TOC visit (Day 5, 6 ,or 7)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population
ParticipantsGeneric Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo Tablets
Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population919586
Statistical analysis
  • Generic Rifaximin 200 mg Tablets vs Rifaximin Placebo Tablets · Z-test · p = 0.7899 (Threshold of significance at 0.05 level.) · Difference in percentage of participants: -0.0195 · 95% CI -0.09 to 0.13
  • Xifaxan 200 mg Tablets vs Rifaximin Placebo Tablets · Z-test · p = 0.5987 (Threshold for significance at 0.05 level.) · Difference in percentage of participants: 0.0330 · 95% CI -0.07 to 0.14

Adverse events

Collected over Day 1 up to Day 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Generic Rifaximin 200 mg Tablets0/246 (0%)0/246 (0%)17/246 (6.9%)
Xifaxan 200 mg Tablets0/247 (0%)0/247 (0%)17/247 (6.9%)
Rifaximin Placebo Tablets0/244 (0%)0/244 (0%)24/244 (9.8%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventGeneric Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo Tablets
Rectal tenesmusGastrointestinal disorders3/2464/2478/244
FlatulenceGastrointestinal disorders4/2463/2474/244
Abdominal painGastrointestinal disorders3/2460/2473/244
NauseaGastrointestinal disorders0/2463/2473/244
HeadacheNervous system disorders2/2462/2473/244
Defecation urgencyGastrointestinal disorders1/2461/2472/244
LymphocytosisBlood and lymphatic system disorders0/2460/2471/244
Alanine aminotransferase increasedInvestigations0/2460/2471/244
NeutropeniaBlood and lymphatic system disorders0/2460/2471/244
ThrombocytopeniaBlood and lymphatic system disorders1/2460/2471/244

Baseline characteristics

Randomized population included all the participants who satisfied the inclusion and exclusion criteria and were randomized into the study.

Age, Continuous
Age, Continuous(years)Generic Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo TabletsTotal
Mean42.5 ± 15.7844.3 ± 16.5842.0 ± 15.2142.9 ± 15.87
Sex: Female, Male
Sex: Female, Male(Participants)Generic Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo TabletsTotal
Female123130132385
Male124118112354
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Generic Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo TabletsTotal
Hispanic or Latino189188188565
Not Hispanic or Latino585854170
Unknown or Not Reported0224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Generic Rifaximin 200 mg TabletsXifaxan 200 mg TabletsRifaximin Placebo TabletsTotal
American Indian or Alaska Native0000
Asian3227
Native Hawaiian or Other Pacific Islander0000
Black or African American23181354
White208222220650
More than one race135927
Unknown or Not Reported0101
08

Study locations

1 site
  • Site 1
    Coral Gables, Florida 33134, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Feb 2017, 13 months.

Results were first posted in Dec 2019, 2 years 9 months after primary completion.

Of 30 phase 3 interventional studies under Diarrhea, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 38. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Jul 15, 2015
StartActual
Jan 6, 2016
Primary completionActual
Feb 28, 2017
CompletionActual
Feb 28, 2017
Results first posted
Dec 5, 2019
Last update
Dec 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02498418
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Jul 15, 2015
Start date
Jan 6, 2016
Primary completion
Feb 28, 2017
Completion
Feb 28, 2017
Results posted
Dec 5, 2019
Last update
Dec 5, 2019

Study contacts

Study Director
study director · Actavis Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion